U.S. markets open in 9 minutes
  • S&P Futures

    3,843.50
    +15.50 (+0.40%)
     
  • Dow Futures

    31,354.00
    -17.00 (-0.05%)
     
  • Nasdaq Futures

    12,948.25
    +116.50 (+0.91%)
     
  • Russell 2000 Futures

    2,202.60
    +2.60 (+0.12%)
     
  • Crude Oil

    62.44
    -1.09 (-1.72%)
     
  • Gold

    1,759.90
    -15.50 (-0.87%)
     
  • Silver

    26.93
    -0.75 (-2.73%)
     
  • EUR/USD

    1.2127
    -0.0059 (-0.49%)
     
  • 10-Yr Bond

    1.4650
    -0.0530 (-3.49%)
     
  • Vix

    27.51
    +6.17 (+28.91%)
     
  • GBP/USD

    1.3971
    -0.0042 (-0.30%)
     
  • USD/JPY

    106.3720
    +0.1420 (+0.13%)
     
  • BTC-USD

    46,277.44
    -5,272.06 (-10.23%)
     
  • CMC Crypto 200

    925.95
    -7.19 (-0.77%)
     
  • FTSE 100

    6,546.38
    -105.58 (-1.59%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation

  • Oops!
    Something went wrong.
    Please try again later.
Elizabeth Balboa
  • Oops!
    Something went wrong.
    Please try again later.

Unity Biotechnology Inc (NASDAQ: UBX) has fallen 22 percent since its May 3 initial public offering. Nonetheless, three sell-side firms initiated price targets implying significant upside Tuesday.

The Rating

Morgan Stanley analysts Matthew Harrison and David Lebowitz initiated coverage on Unity with an Overweight rating and $25 price target.

The Thesis

The analysts are inspired by “novel biology” and compelling preclinical data.

Unity hypothesizes that it can heal chronic illness such as osteoarthritis and eye disease by eliminating non-dividing cells that otherwise drive inflammation through protein build-ups. It recently released preclinical data demonstrating a 35-percent increase in mice longevity with no sign of arthritis and fewer instances of cataracts.

“While [the] initial focus of knee arthritis is narrow, we believe proof-of-concept could lead to platform validation,” the analysts said in a note.

Clinical data on osteoarthritis is expected as soon as the first quarter of 2019 and could catalyze stock movement, according to Morgan Stanley.

Unity Biotechnology also intends to file Investigational New Drug applications next year to expand the platform.

Price Action

Unity shares were up 0.15 percent at $13.02 at the close Tuesday.

Related Links:

T2Biosystems Announces FDA Approval For Sepsis Test: 'This Is A Game-Changer'

Transenterix Pops On FDA Clearance For Senhance Indication Expansion

Latest Ratings for UBX

May 2018

Citigroup

Initiates Coverage On

Buy

May 2018

Goldman Sachs

Initiates Coverage On

Neutral

May 2018

Morgan Stanley

Initiates Coverage On

Overweight

View More Analyst Ratings for UBX
View the Latest Analyst Ratings

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.